EUVIMEDOpdag EUVIMED
Open access · CC BY 4.0

LRH ‐1 activation alleviates diabetes‐induced podocyte injury by promoting GLS2 ‐mediated glutaminolysis

Jijia Hu iD, Zongwei Zhang, Hongtu Hu, Keju Yang, Zijing Zhu, Qian Yang, Wei Liang

Cell Proliferation · 2023

DOI: 10.1111/cpr.13479 ↗

At a glance

Journal article in Cell Proliferation, 2023. Written by Jijia Hu and 6 co-authors. Institution: Division of Nephrology, Renmin Hospital of Wuhan University, Wuhan, Hubei, China. Major MEDLINE topics: Diabetes Mellitus, Experimental, Diabetic Nephropathies, Podocytes. Cited 16 times so far (Crossref); 40 references. The full text is freely available (open access, CC BY 4.0). Funded by: National Natural Science Foundation of China, Natural Science Foundation of Hubei Province.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Alteration of metabolic phenotype in podocytes directly contributes to the development of albuminuria and renal injury in conditions of diabetic kidney disease (DKD). This study aimed to identify and evaluate liver receptor homologue‐1 (LRH‐1) as a possible therapeutic target that alleviates glutamine (Gln) metabolism disorders and mitigates podocyte injury in DKD. Metabolomic and transcriptomic analyses were performed to characterize amino acid metabolism changes in the glomeruli of diabetic mice. Next, Western blotting, immunohistochemistry assays, and immunofluorescence staining were used to detect the expression of different genes in vitro and in vivo. Furthermore, Gln and glutamate (Glu) content as well as ATP generation were examined. A decrease in LRH‐1 and glutaminase 2 (GLS2) expression was detected in diabetic podocytes. Conversely, the administration of LRH‐1 agonist (DLPC) upregulated the expression of GLS2 and promoted glutaminolysis, with an improvement in mitochondrial dysfunction and less apoptosis in podocytes compared to those in vehicle‐treated db/db mice. Our study indicates the essential role of LRH‐1 in governing the Gln metabolism of podocytes, targeting LRH‐1 could restore podocytes from diabetes‐induced disturbed glutaminolysis in mitochondria.

Subjects

MeSH terms (MEDLINE)

Diabetes Mellitus, ExperimentalDiabetic NephropathiesPodocytesAnimalsMiceKidneyKidney GlomerulusReceptors, Cytoplasmic and NuclearGlutaminase

Substances

Nr5a2 protein, mouseReceptors, Cytoplasmic and NuclearGls2 protein, mouseGlutaminase

Authors and institutions

  • Division of Nephrology, Renmin Hospital of Wuhan University, Wuhan, Hubei, China.
  • Nephrology and Urology Research Institute of Wuhan University, Wuhan, Hubei, China.
  • The First College of Clinical Medical Science, China Three Gorges University, Yichang, Hubei, China.

ORCID profiles: Jijia Hu

Funding

  • National Natural Science Foundation of China
  • Natural Science Foundation of Hubei Province

Cite

APA

Hu, J., Zhang, Z., Hu, H., Yang, K., Zhu, Z., Yang, Q., & Liang, W. (2023). LRH ‐1 activation alleviates diabetes‐induced podocyte injury by promoting GLS2 ‐mediated glutaminolysis. Cell Proliferation. https://doi.org/10.1111/cpr.13479

Vancouver

Hu J, Zhang Z, Hu H, Yang K, Zhu Z, Yang Q, et al. LRH ‐1 activation alleviates diabetes‐induced podocyte injury by promoting GLS2 ‐mediated glutaminolysis. Cell Proliferation. 2023. doi:10.1111/cpr.13479

BibTeX
@article{Hu2023,
  author = {Hu, Jijia and Zhang, Zongwei and Hu, Hongtu and Yang, Keju and Zhu, Zijing and Yang, Qian and Liang, Wei},
  title = {LRH ‐1 activation alleviates diabetes‐induced podocyte injury by promoting GLS2 ‐mediated glutaminolysis},
  journal = {Cell Proliferation},
  year = {2023},
  doi = {10.1111/cpr.13479}
}
Start for free →